Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

NCT06725498 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Tislelizumab-jsgr
DRUG: Cisplatin
DRUG: Albumin-Bound Paclitaxel
RADIATION: Radiotherapy

Sponsor

Beijing Tongren Hospital